Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 45, Issue 6

Issues

The role of in vitro diagnostic companies in reducing laboratory error

Ana K. Stankovic
  • 1Medical and Clinical Affairs, BD Diagnostics, Preanalytical Systems, Franklin Lakes, NJ, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Peter Romeo
  • 2Global Product Development System, BD Diagnostics, Preanalytical Systems, Franklin Lakes, NJ, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2007-06-19 | DOI: https://doi.org/10.1515/CCLM.2007.175

Abstract

Laboratory errors have a significant impact on patient safety. The manufacturers of in vitro diagnostic (IVD) products play an important role in the reduction of laboratory errors by ensuring the highest possible safety and efficacy of their products. In order to achieve this, the IVD industry has implemented rigorous product development and manufacturing processes. Many IVD companies apply Six Sigma principles in order to minimize variability within the whole product life cycle, starting with customer requirements, through product design and manufacture, as well as management of the potential issues that occur after the products have been released for use. A closer look into this process is presented here, using an evacuated blood collection tube as a model device.

Clin Chem Lab Med 2007;45:781–8.

Keywords: design for Six Sigma; Define-Measure-Analyze-Improve-Control (DMAIC); evacuated tubes; in vitro diagnostic (IVD) products; laboratory errors; New Product Development; patient safety; preanalytical variables; product development; Six Sigma

About the article

Corresponding author: Ana K. Stankovic, MD, PhD, MSPH, World Wide Vice President, BD Diagnostics, Preanalytical Systems MC310, 1 Becton Drive, Franklin Lakes, NJ 07417, USA Phone: +1-201-8474376, Fax: +1-201-8474851,


Published Online: 2007-06-19

Published in Print: 2007-06-01


Citation Information: Clinical Chemical Laboratory Medicine, Volume 45, Issue 6, Pages 781–788, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: https://doi.org/10.1515/CCLM.2007.175.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Ulrich-Peter Rohr, Carmen Binder, Thomas Dieterle, Francesco Giusti, Carlo Guiseppe Mario Messina, Eduard Toerien, Holger Moch, Hans Hendrik Schäfer, and Yue Wang
PLOS ONE, 2016, Volume 11, Number 3, Page e0149856
[2]
Abdel-Baset Halim
Laboratory Medicine, 2013, Volume 44, Number 1, Page e19
[3]
Abdel-Baset Halim
Biomarkers in Medicine, 2011, Volume 5, Number 2, Page 211
[4]
Elvar Theodorsson
Bioanalysis, 2012, Volume 4, Number 3, Page 305
[5]
Raffick A.R. Bowen, Glen L. Hortin, Gyorgy Csako, Oscar H. Otañez, and Alan T. Remaley
Clinical Biochemistry, 2010, Volume 43, Number 1-2, Page 4

Comments (0)

Please log in or register to comment.
Log in